HTT and Huntington disease: The intrastriatal administration of gene therapy with a recombinant adeno-associated virus serotype 5 expressing a microRNA (miRNA) targeting HTT (AAV5-miHTT) also holds promise for lowering mRNA and HTT protein in the brain and slowing HD progression [6,7].